

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_81059
Title of the Manuscript:	ROLE OF TOCILIZUMAB IN FIGHTING COVID 19
Type of the Article	Review Article

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

### **PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ol style="list-style-type: none"><li>1. Should be explained methods in the study especially in abstract section (method in the review study, and in the content of the article)</li><li>2. Be detailed to explain the correlation of tocilizumab with comorbidity and preventive of COVID-19 in the content of the each sub title</li><li>3. Vaccination not the focus study in the review, should be showed more in the study</li></ol>	
<b>Minor</b> REVISION comments	<ol style="list-style-type: none"><li>1. Should be double check the English writing in each sentence</li></ol>	
<b>Optional/General</b> comments	Should be accepted the review article with several revisions	

### **PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

### **Reviewer Details:**

Name:	Blego Sedionoto
Department, University & Country	Muawarman University, Indonesia